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A B S T R A C T   
The immunohistochemical pattern of kynurenine aminotransferase-2 (KAT-2) - the key role enzyme in the 
production of neuroactive and neuroprotective kynurenic acid (KYNA) - was studied in the cerebellum of mice. It 
is known from literature that KAT-2 is localized mainly in astrocytes in different parts of the cerebrum. 
Kynurenine aminotransferase (KAT) activity in the cerebellum is relatively low and alternative production routes 
for KYNA have been described there. Therefore we examined the immunohistochemical pattern of KAT-2 in this 
part of the brain. Surprisingly, the cellular localization of KAT-2 in mice was proven to be unique; it localized 
characteristically in Purkinje cells and in some other types of neurons (not identified) but was not found in 
astrocytes nor microglia. The exclusive neuronal, but not glial localization of KAT-2 in the cerebellum is novel 
and may be related to its low activity and to the alternative pathways for KYNA production that have been 
described.   
1. Introduction 
Kynurenic acid (KYNA) is one of the neuroactive end-products of the 
kynurenine pathway (KP) of tryptophan degradation, which has multi-
ple effects in the mammalian brain (Fujigaki et al., 2017). Alone or 
jointly, these effects play an important role in the mechanism of neu-
roprotective and neuromodulatory effects of endogenous KYNA in the 
central nervous system. Consequently, the pathological change of KP 
balance may result in hypo- or hyperfunction of neuroactive metabo-
lites, which is associated with neurological, as well as psychiatric dis-
eases (Vécsei et al., 2013). One of the major questions is the biosynthesis 
of KYNA within the brain, which has been examined in considerable 
detail. Up to now, four aminotransferases have been shown to catalyze 
the transamination of the pivotal KP metabolite L-kynurenine to KYNA 
(Han et al., 2010). Out of the four isoforms of KAT enzymes, KAT-2 is of 
greatest importance both in the murine and the human brain (Nem-
atollahi et al., 2016). Due to the importance of KATs in regulating the 
level of KYNA, studies aimed to describe the spatiotemporal expression 
pattern of the different KATs at the cellular level, and it was found in the 
rat brain that KAT-2 is localized mainly in astrocytes (Guidetti et al., 
2007), which glial cells release in situ “de novo” synthesized KYNA. 
Kynurenic acid production and release from the astrocytes and brain 
slices were studied in detail (Turski et al., 1989), and turned out that 
KAT-2 is expressed in other cells too, including neurons (Herédi et al., 
2017). 
The role of KP in neurodegenerative and neuropsychiatric diseases is 
evident (Vécsei et al., 2013), consequently the investigation of that topic 
is essential. However, most studies were carried out on rat models and 
human samples. In addition to it, these studies were focused on different parts 
of the forebrain but not on the cerebellum. In recent years we started to 
study the KAT activity in mice (Herédi et al., 2017, 2019). The impor-
tance of these experimental animals in these studies is also evident, 
considering that mice strains are the main subjects of gene manipula-
tion. To our best knowledge, there is no description of KAT-2 immu-
nohistochemistry in the cerebellum of mice. 
This study aimed to investigate the possible localization of KAT-2 
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enzyme in the cerebellum of mice and to answer these questions: i) is 
there any sign of KAT-2 enzyme in the cerebellum, ii) if yes, is it local-
ized in glial cells and/or in neurons? 
2. Materials and methods 
2.1. Animals 
12-14-week-old male C57Bl/6 mice obtained from The National 
Fig. 1. Investigating the distribution of 
KAT-2+ cells in the mouse cerebellum with 
fluorescent immunohistochemistry using 
neuronal markers. A: Widely distributed 
KAT-2+ neurons (red) were found in the 
whole mouse cerebellum, among them the 
most expressive were the Purkinje cells 
(insert: Purkinje cells in larger magnifica-
tion). Scale bars: 400 μm (A) and 40 μm 
(insert). The photomicrographs (C, E, G) in 
the right column correspond to the rectan-
gles in photomicrographs B, D, F, with 
higher magnifications. B–C: Double labeling 
of KAT-2 (red) with the neuronal marker 
NeuN (green). The NeuN protein is not 
present in Purkinje cells, while KAT-2 shows 
strong expression (arrows). D-E: Double la-
beling of KAT-2 (red) with GABAergic 
neuronal marker GAD67 (green). KAT-2 
and GAD67 showed complete overlap (or-
ange). Not only Purkinje cells (arrows), but 
other GABAergic neurons express KAT-2 as 
well (asterisk). F-G: Double labeling of KAT- 
2 (red) with calcium-binding protein 
neuronal marker Calbindin (green). 
Several types of neurons express Calbindin, 
including Purkinje cells. In the Purkinje cell 
layer, Calbindin and KAT-2 showed signifi-
cant co-localization (arrows). Scale bars: 40 
μm (B, D, F) and 20 μm (C, E, G).   
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Institute of Oncology (Budapest, Hungary) were used (n = 12) for his-
tological studies. Animals were kept under controlled laboratory con-
ditions and had free access to food and water. All experiments complied 
with the guidelines of the European Communities Council Directives 
(2010/63/EU) and the Hungarian Act for the Protection of Animals in 
Research (XXVIII.tv. 32. §) and were approved by the ethical license: I- 
74-16/2015. 
2.2. Tissue preparation 
For the immunohistochemical experiments animals were deeply 
anesthetized with an intraperitoneal injection of urethane (1.6 g/bwkg) 
and were perfused transcardially with ice-cold 0.1 M phosphate buffer 
(PB, pH 7.4) following 4% paraformaldehyde (PFA, dissolved in 0.1 M 
PB, pH 7.4). The brains were removed and post-fixed overnight in 4% 
PFA at 4 ◦C. 20 μm coronal sections were obtained with a vibratome 
Fig. 2. Investigating the distribution of 
KAT-2+ cells in the mouse cerebellum 
with fluorescent immunohistochemistry 
using glial markers. Photomicrographs 
(B, D, F, H) in the right column corre-
spond to the rectangles in photomicro-
graphs (A, C, E, G) with higher 
magnifications. A-B: Double labeling of 
KAT-2 (red) with astrocyte marker 
GFAP (green). The processes of GFAP+
glial cells surround the soma of KAT-2+
neurons (arrowheads), but double la-
beling of GFAP and KAT-2 cannot be 
observed (arrows). C-D: Double labeling 
of KAT-2 (red) with astrocytic end-feet 
marker AQP4 (green). KAT-2 expres-
sion was detected in neurons (arrows) 
but not in the astrocytic end-feet. E-F: 
Double labeling of KAT-2 (red) with 
microglia marker CD11b (green). The 
CD11b+ microglial cells surround the 
KAT-2+ neurons (arrowhead). However, 
double labeling of CD11b and KAT-2 
cannot be detected (arrows). G-H: 
Double labeling of KAT-2 (red) with 
microglia marker Iba1 (green). Similar 
to the results of CD11b labeling, we 
observed microglial cells’ processes 
surrounding Purkinje cells (arrow-
heads), but there was no KAT-2 posi-
tivity in the microglia (arrows). Scale 
bars: 40 μm (A, C, E, G) and 20 μm (B, 
D, F, H).   
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Free-floating sections were washed in PB containing 0,4% Triton X- 
100 (PBT) and incubated in 2% normal donkey serum (NDS) at room 
temperature. For the detection of KAT-2 and identification of cells 
containing the enzyme, the sections were exposed to primary antibodies 
(rabbit anti-KAT-2, 1:1000, Proteintech; rat anti-GFAP, 1:4000, Sigma; 
mouse anti-NeuN, 1:4000, Millipore; mouse anti-GAD67, 1:1000, Mil-
lipore and mouse anti-Calbindin, 1:1500, Swant; rat anti-CD11b, 1:200, 
Bio-Rad; goat anti-Iba1, 1:400, Abcam and mouse anti-AQP4, 1:200, 
Sigma) overnight at 4 ◦C. 
The next day, samples were incubated in the appropriate secondary 
antibodies (1:500; Jackson Immuno Research) for 2 h at room temper-
ature. Primary antibodies were diluted in 0.1 M PBT containing 1% NDS, 
while secondary antibodies were diluted in 0.1 M PB. Negative control 
was prepared from sections incubated without the primary antibodies. 
After the incubations, the sections were coverslipped with antifade 
mounting medium (ProLong® Gold, Life Technologies). Fluorescent 
photomicrographs were obtained with an Olympus BX51 microscope 
fitted with a DP70 digital imaging system and a Zeiss Axio Imager 2 
microscope. 
3. Results 
The presence of KAT-2 was studied with single and double fluores-
cent immunolabeling using neuronal and glial markers. We observed 
broad KAT-2 distribution in the whole mouse cerebellum (Fig. 1A). 
Using double fluorescent immunolabeling we found neurons in different 
cerebellar layers, with distinct size and appearance, which were positive 
both for NeuN and KAT-2, except for the Purkinje cell layer (Fig. 1B). In 
Purkinje cells, only KAT-2 labeling was found, and this KAT-2 positivity 
was prominent (Fig. 1B and C). To further verify the Purkinje cell 
identity, and to detect other GABAergic neurons in the cerebellum, 
GAD67 (Fig. 1D) and Calbindin (Fig. 1F) markers were used. Both 
GAD67 and Calbindin are expressed in several types of neurons, 
including Purkinje cells. These markers showed complete overlap with 
KAT-2+ Purkinje cells (Fig. 1 E, G arrows). These results undoubtedly show 
that the most prominent KAT-2 positive cells in the cerebellum are Purkinje 
cells. That was indicated by i) labeling with GAD67 and by ii) labeling 
with Calbindin, iii) cell diameter and iiii) the lack of labeling with NeuN 
as an indirect proof. 
GFAP astrocyte marker (Fig. 2A) and AQP4 astrocytic end-feet 
marker (Fig. 2C) were used to identify astrocytes and to examine the 
glial expression of KAT-2. Although KAT-2 has been described in the 
cerebrum partly as a glial enzyme (mainly astrocytic), it is not expressed 
either in astrocytes (Fig. 2B) or in astrocytic end-feet surrounding Pur-
kinje cells in the investigated regions of the cerebellum (Fig. 2D). 
Microglial cells were labeled with CD11b (Fig. 2E) and Iba1 microglia 
markers (Fig. 2G). Both with CD11b and Iba1 markers we observed 
microglial cells’ processes surrounding Purkinje cells (Fig. 2F, H ar-
rowheads), but there was no KAT-2 positivity in the microglia. 
4. Discussion 
Kynurenine aminotransferase has four isoforms (KAT-1, -2, -3, -4) 
which are capable of catalyzing the transamination of L-kynurenine to 
KYNA. KAT-2 has the highest importance in the mammalian brain 
(Nematollahi et al., 2016). The present study demonstrated for the first 
time that KAT-2 enzyme did not localize in astrocytes, but notable 
expression was observed in the Purkinje cells of mice cerebellum. The 
finding that the prominently labeled cells are Purkinje cells is strongly 
supported by the position of their layer, the size of the cell, the fact that 
they can be labeled with GAD67 and Calbindin, and mostly by the fact 
that they are not labeled by NeuN. It is a well-known fact that the 
sympathetic chain ganglia, the cells of the internal nuclear layer of the 
retina, and the Purkinje cells are immunonegative for NeuN (Wolf et al., 
1996). Therefore, GAD67 and Calbindin markers were used for the 
identification of Purkinje cells. The finding that in the cerebellum of 
mice, KAT-2 is expressed in neurons (mainly in Purkinje cells) but not in 
astrocytes is not only new but also surprising, since KAT-2 enzyme in rat 
localizes mostly in astrocytes in different parts of the cerebrum (Guidetti 
et al., 2007). 
One of our recent studies in mice showed that KAT-2 is expressed not 
only in astrocytes but also in interneurons in different structures of the 
cerebrum (Herédi et al., 2017). 
Based on these results, one can say that KAT-2 in the cerebrum of 
different species is expressed in astrocytes and also in other cell types, 
including neurons. On the other hand, in the cerebellum of mice KAT-2 
is expressed in neurons (mainly in Purkinje cells, and also in other types 
of interneurons) but not in astrocytes. Besides this finding also draws our 
attention to species-specific differences in KAT-2 immunoreactivity in 
the central nervous system: in the rat cerebellum, KAT-2 has been re-
ported to be localized in astrocytes but not in Purkinje cells (Guidetti 
et al., 2007). According to the literature, there is another major differ-
ence between mice and rats. In contrast to rats, KAT-2 plays only a minor 
role in kynurenic acid production in the brain of adult mice (Yu et al., 
2004). 
Even if KAT-2 plays only a minor role in kynurenic acid production in 
the brain of adult mice, the prominent KAT-2 expression in Purkinje cells 
raises an interesting question. If we accept that the Purkinje cell itself 
(which has a key role in the cerebellar network) produces and releases in 
situ “de novo” synthesized KYNA, it may have widespread modulatory 
effects. For example, it may also suggest the existence of an autor-
egulatory activity on these neurons. It is because KYNA-sensitive post-
synaptic responses were recorded at the proximal pole of the Purkinje 
cell dendrites evoked by climbing fibers (Lopez et al., 1991). 
The ontogenetic pattern of KAT activity in different parts of the brain 
was studied in detail. The KAT activity increased in all regions of the rat 
brain between 3rd postnatal day and 3rd months. However, the KAT 
activity was always the lowest in the cerebellum (Baran and Schwarcz, 
1993). At the same time, alternative KYNA synthesis routes were 
described in the cerebellum. Generally, KYNA is attributed to the 
enzymatic conversion of L-kynurenine by KATs. In the cerebellum, it 
was found that KYNA may be produced from D-kynurenine by D-amino 
acid oxidase and by direct transformation of kynurenine to KYNA by 
reactive oxygen species (Blanco Ayala et al., 2015). These alternative 
ways are highly efficient in the cerebellum (Wang et al., 2012; Blanco 
Ayala et al., 2015). 
According to the literature cited above and to our studies, KAT-2 is 
expressed in the brain in a region and cell type-specific manner, as Song 
and coworkers suggested (Song et al., 2018). 
Because of the increasing attention that is paid to the role of 
endogenous kynurenic acid in brain physiology and pathology, the 
demonstration of fundamental differences in the cellular localization of 
KAT-2 in the forebrain and the cerebellum has far-reaching implications. 
Therefore, we tried to pay special attention to the specificity of our 
antibody. 
The validation of our antibody has happened earlier with several 
molecular biological methods. We performed immunohistochemistry on 
mouse brain sections and immunocytochemistry on the HeLa cell culture 
transfected with mouse kat-2 cDNA. We observed no KAT-2 positivity in 
the negative controls. 
In addition to the immunohistochemical studies, we tested the pri-
mary antibody specificity with Western blot analysis both on transfected 
HeLa cell culture and on mouse brain tissue homogenates from cere-
brum and cerebellum. We detected a single immunoreactive band in the 
transfected HeLa cell culture preparation and the cerebral and cerebellar 
tissue homogenates at ~47 kDa, which is the estimated size of KAT-2 
(not shown here, Herédi et al., 2017). 
Considering the antibody validation results mentioned above we did 
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not carry out an experiment in which parallel tissue sections were 
incubated with the antibody that had been preadsorbed with pure an-
tigen and we did not verify the inhibition of KAT-2 enzyme activity by 
our antibody. 
We are convinced that KAT-2 labeling shows a unique pattern in the 
cerebellum, which may be related to the multiple ways of KYNA pro-
duction (low level of the classical way of KYNA production, low KAT 
activity) and the existence of alternative KYNA synthesis routes. 
In summary, the present study is the first to report the prominent 
expression of KAT-2 in Purkinje cells but the lack of glial protein 
expression in mice cerebellum. Further studies are needed to clarify i) 
the functional role of KAT-2 expression in cerebellar Purkinje cells and 
ii) the role of KAT-2 expression in other types of neurons in mice 
cerebellum. 
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Herédi, J., Berkó, A.M., Jankovics, F., Iwamori, T., Iwamori, N., Ono, E., Horváth, S., 
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